August Cannabis M&A: Curaleaf, Vireo, and a Foreclosure Wave

August 2026 cannabis M&A moved into a different weight class. Curaleaf announced a US$4 per share takeover bid for Aurora Cannabis on August 10 and formally commenced the offer on August 18, a 45% premium, $1.5 billion plus in pro forma combined revenue, and a clear signal that major multi state cannabis companies (MSOs) are thinking cross border. Meanwhile, Vireo Growth closed its $49 million PharmaCann Colorado acquisition, announced the Planet 13 merger, and continued assembling what would be the largest dispensary portfolio in the country by store count. Distressed sales accelerated in Massachusetts, New Mexico, Pennsylvania, and New Jersey, as lender driven exits moved from threat to closing table. Nine qualifying transactions tracked this month across six states, with buyer concentration in Colorado cannabis M&A activity, New York, and the MSO consolidation tier.

🔥 MARKET SIGNALS THIS MONTH:

• A notable cross border MSO takeover bid, Curaleaf’s offer for Aurora Cannabis at a 45% premium signals a new era of consolidation scale
• Vireo Growth assembling a potential 270 dispensary national footprint through back to back closings and merger agreements in a single quarter
• Lender driven forced sales now confirmed across four states (MA, NM, PA, NJ), with Advanced Flower Capital collateral events in Massachusetts and scheduled Article 9 sales in Pennsylvania and New Jersey
• California’s large footprint operators remain under lender pressure, with the Element 7 receivership auction held June 12 and regulated sales still declining against unlicensed competition

New York: Acquisition

Grown Rogue International is acquiring PharmaCann Inc.‘s New York cannabis license and assets through a joint venture (Grown Rogue New York LLC, 51% Grown Rogue / 49% capital partner) for an estimated $4.5 million acquisition price, with $3 million payable on regulatory approval. The package includes a 24,000 sq. ft. Hamptonburgh cultivation and manufacturing facility and four Verilife branded dispensaries averaging $1.7 to 2.0 million in aggregate monthly sales.

Definitive agreements expected within four weeks of the August 21 announcement, subject to regulatory approval.

🔥 Massachusetts: Distressed Sale

Two DMA Holdings backed dispensaries were sold through a receiver in July 2026, according to Advanced Flower Capital second quarter disclosures reported on its August 20 earnings call. This confirms a pattern of margin driven distressed sales in a heavily levered state market.

No buyer name was disclosed in lender reporting.

Massachusetts / New Mexico: Distressed Sale (Binding Term Sheet)

Devi Holdings, through its court appointed receiver, entered a binding term sheet to sell its Massachusetts and New Mexico assets to J Brothers LLC for $12.5 million, with a $2.0 million non refundable deposit earned after quarter end. Advanced Flower Capital has recovered $58 million in principal on the Devi loan to date.

The transaction has not closed.

Pennsylvania / New Jersey: Distressed Sale (Scheduled)

Advanced Flower Capital‘s loan to Justice Grown (Justice Cannabis Company) matured May 1, 2026 and is in maturity default, with approximately $78.8 million principal outstanding against a fair value of $42.0 million as of June 30, 2026. AFC has commenced Article 9 foreclosures and engaged SSG Advisors to market the collateral, with Pennsylvania cannabis assets scheduled for September 24, 2026 and New Jersey dispensary collateral on October 6, 2026.

A court hearing is set for September 15. No buyer names have been disclosed.

Colorado: Acquisition (Closed August 7, 2026)

Vireo Growth Inc. completed its acquisition of 17 PharmaCann Inc. Colorado retail dispensaries for approximately $49.0 million in Vireo subordinate voting shares and assumed liabilities, expanding its Colorado retail footprint to 56 locations. Vireo managed the PharmaCann Colorado operations under a Management Services Agreement from March 2026 through closing, enabling operational integration before the regulatory transfer was finalized.

This adds significantly to Vireo’s ongoing national roll up.

🔥 Colorado: Acquisition (Closed)

Verdant Capital Partners completed its acquisition of 15 Native Roots retail dispensaries in Colorado effective July 31, 2026, following receipt of all required regulatory approvals. Native Roots, founded in 2009, will continue operating under its existing brand while Verdant assumes ownership and operational control. This is Verdant’s first retail platform acquisition as it executes a strategy to build through cannabis retail consolidation in regulated U.S. markets, a new private capital buyer entering Colorado at a moment of significant industry wide distress.

Financial terms were not disclosed.

🔥 Multi-State: Merger (Announced July 26, 2026)

Vireo Growth Inc. entered into an Agreement and Plan of Merger with Planet 13 Holdings Inc., with Planet 13 continuing as a direct wholly owned subsidiary of Vireo through a merger with Supernova Merger Sub Inc. Vireo currently operates in 10 states with approximately 170 dispensaries and reported pro forma Q2 2026 revenue of $254.9 million with 7% same store sales growth across acquired assets. With pending transactions including FLUENT, C21, and the Planet 13 merger, Vireo is positioned to operate approximately 270 dispensaries across 15 to 16 states, targeting the title of largest U.S. cannabis company by dispensary count.

The all stock exchange ratio is 0.015383618 Vireo subordinate voting shares per Planet 13 share, a roughly 16.6% premium to Planet 13’s 20 day VWAP as of July 24, 2026.

🔥 Multi-State / Cross-Border: Takeover Bid (Announced August 10, 2026; formally commenced August 18, 2026)

Curaleaf Holdings Inc. launched a takeover bid to acquire all outstanding common shares of Aurora Cannabis Inc. at US$4 per share, comprised of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, representing a 45% premium to Aurora’s unaffected 30 day VWAP of US$2.75 and a 110% premium on an ex cash basis. The combined company would carry pro forma revenue exceeding US$1.5 billion and adjusted EBITDA of nearly US$350 million, with at least US$40 million in identified annual cost synergies.

The offer is open until 5 p.m. Mountain Time on December 1, 2026, is not subject to financing or due diligence conditions, and requires more than 50% of shares held by independent shareholders plus at least two thirds on a fully diluted basis.

National (OTC): Controlling Interest Acquisition (Closed June 29, 2026)

Trafalgar Asset Management LLC, owned by Porfirio Sanchez Talavera, acquired 7,628,665 Series A Preferred shares and 1,000 Series B Preferred shares in The Greater Cannabis Company Inc., obtaining 96.62% aggregate voting power. Sanchez Talavera was appointed CEO, Chairman, and sole director, with a full executive team installed.

This is a small cap OTC controlling interest acquisition with no disclosed consideration beyond the share transfer.

Deal Spotlight: Curaleaf vs. Aurora Cannabis

Curaleaf’s takeover bid for Aurora Cannabis, announced August 10 and formally commenced August 18, is a highly consequential cannabis M&A announcement this year. The structure, partial cash, partial shares, no financing condition, says Curaleaf is serious and has the balance sheet to back it. A US$3 billion plus combined market cap, nearly $350 million in pro forma EBITDA, and exposure across the U.S., Canada, and Germany would give the merged entity one of the broadest footprints in the cannabis industry. The strategic logic is scale: Aurora brings German medical market share (a regulated, high value market), Canadian production infrastructure, and geographic diversification that few U.S. only MSOs can replicate. The risk is execution. Cross border integration of two heavily leveraged companies, each carrying significant legacy costs, is operationally complex. Watch for a competing bid or activist shareholder response before October.

Lender forced exits are no longer theoretical. Advanced Flower Capital disclosed three active distressed positions in one quarter: Massachusetts DMA Holdings (two stores sold by receiver), Devi Holdings (binding term sheet at $12.5 million for Massachusetts and New Mexico assets), and Justice Grown (PA/NJ Article 9 sale dates confirmed). The roughly $6 billion in cannabis debt maturing by end of 2026 is converting into actual asset sales at steep discounts.

Vireo’s roll up is rewriting scale benchmarks. Three major closings and four additional definitive agreements in a single quarter, targeting 270 dispensaries across 15 to 16 states. This pace stands out compared to peers’ more measured M&A approaches. The question isn’t whether Vireo gets there, it’s whether integration at this speed produces durable same store performance.

California’s licensed market is under continued pressure. The Element 7 receivership auction on June 12, alongside persistent lender pressure, reflects a market with substantial unlicensed competition and declining regulated sales. Large footprint California cannabis companies with acquisition era debt are among the more exposed businesses nationally.

Private capital is entering Colorado retail. Verdant Capital Partners’ Native Roots acquisition is a new buyer category, a private investment vehicle with a cannabis co founder executing a multi site retail consolidation. Colorado’s competitive market is creating acquisition prices that make private equity math work.

Cross border M&A is now on the table. Curaleaf’s Aurora bid signals that the April 2026 partial rescheduling and an improving capital backdrop have created conditions where a U.S. MSO can pursue a Canadian target with a realistic path to closing. Note that the rescheduling order applies to FDA approved products and state licensed medical marijuana only; adult use marijuana remains Schedule I, and the DEA’s broader rescheduling hearing opened June 29. This deal, if it closes, opens a template for U.S. Canada consolidation that will be studied closely by every major MSO.

Port Richmond, Staten Island, NY

Asking: $950,000

• Turnkey pre opening dispensary, ready to operate at closing
• Seller owns the real estate and is open to lease or sale
• 1,200 to 1,300 SF ground floor plus full basement, street parking and lot directly across the street
• Lease at $8,000 to $9,000/mo, 6 to 8 weeks to opening

Park Slope, Brooklyn, NY

Asking: $3,000,000

• Open 12+ months, $2.6M in gross revenue trending up month over month
• $850K in net profit over the trailing 12 months
• 2,000 SF on a 10+ year lease at $25,750/mo with 25,000 daily traffic count
• Strong unit economics with revenue and profitability both climbing

Off Market Manhattan (Two Locations, NDA Required)

Pricing: Available upon execution of NDA

• Two off market dispensaries, one generating $6M+ in annual revenue and one doing over $10M, both with strong EBITDAs
• Each located in a prime Downtown or Midtown Manhattan corridor
• Full financials, addresses, and deal terms available directly with ownership under NDA

The Bronx, NY Freestanding Building

Asking: $1,999,999

• Trending toward $3M in trailing 12 month sales, priced at approximately 0.67x net sales and below prevailing market multiples for comparable New York dispensaries
• Freestanding 6,000 SF building: approximately 2,600 SF ground floor dispensary, 2,600 SF sub leasable second floor, and 600 SF basement
• 10 year lease with two 5 year extension options and subleasing rights included at $35,833/mo

Jersey City, NJ

Asking: $2.8M

• $2.77M in gross sales with 48.45% gross margin, currently in year 4 of a 5 year base lease with two 5 year renewal options at $6,700/mo
• 3 year license with MBE and Impact Zone certifications
• 2,681 SF with consumption lounge ready space and 2 parking spaces

📬 Track Cannabis M&A Every Month

Get monthly cannabis M&A deal flow, valuation data, and market signals delivered to your inbox. Built for investors and executives evaluating acquisition timing.